Sri Krishna
Overview
Explore the profile of Sri Krishna including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
1270
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nema S, Kumari M, Verma K, Krishna S, Ali N, Verma A, et al.
Trans R Soc Trop Med Hyg
. 2025 Mar;
PMID: 40066598
Background: Rapid diagnostic tests (RDTs) are vital for malaria diagnosis, especially in resource-limited areas. RDTs targeting histidine-rich protein 2 (PfHRP2) and its structural homologue PfHRP3 are commonly used for detecting...
2.
Krishna S, Nema S, Sangle R, Ahmad A, Singh A, Kumar D, et al.
PLoS One
. 2024 Dec;
19(12):e0315662.
PMID: 39693284
Rapid diagnostic tests (RDTs) are crucial for diagnosing malaria in resource-limited settings. These tests, which detect the histidine-rich protein 2 (PfHRP2) and its structural homologue PfHRP3, are specifically designed to...
3.
Parkhurst M, Goff S, Lowery F, Beyer R, Halas H, Robbins P, et al.
Nat Med
. 2024 Jul;
30(9):2586-2595.
PMID: 38992129
Adoptive cell transfer (ACT) with neoantigen-reactive T lymphocytes can mediate cancer regression. Here we isolated unique, personalized, neoantigen-reactive T cell receptors (TCRs) from tumor-infiltrating lymphocytes of patients with metastatic gastrointestinal...
4.
Levin N, Kim S, Marquardt C, Vale N, Yu Z, Sindiri S, et al.
J Immunother Cancer
. 2024 May;
12(5).
PMID: 38816232
Background: Tumor-infiltrating lymphocytes (TILs) targeting neoantigens can effectively treat a selected set of metastatic solid cancers. However, harnessing TILs for cancer treatments remains challenging because neoantigen-reactive T cells are often...
5.
Ali N, Nema S, Schneider K, Krishna S, Verma A, Das A, et al.
J Infect Dis
. 2023 Dec;
229(5):1574-1583.
PMID: 38041852
Background: Antimalarial drug resistance surveillance and containment are crucial for countries aiming to eliminate malaria. Monitoring resistance evolution through studies before and after treatment policy changes is essential. Methods: A...
6.
Yossef R, Krishna S, Sindiri S, Lowery F, Copeland A, Gartner J, et al.
Cancer Cell
. 2023 Dec;
41(12):2154-2165.e5.
PMID: 38039963
Circulating T cells from peripheral blood (PBL) can provide a rich and noninvasive source for antitumor T cells. By single-cell transcriptomic profiling of 36 neoantigen-specific T cell clones from 6...
7.
Chatani P, Lowery F, Parikh N, Hitscherich K, Yossef R, Hill V, et al.
J Immunother Cancer
. 2023 May;
11(5).
PMID: 37258038
Background: Cellular immunotherapies using autologous tumor-infiltrating lymphocytes (TIL) can induce durable regression of epithelial cancers in selected patients with treatment-refractory metastatic disease. As the genetic engineering of T cells with...
8.
Kim S, Vale N, Zacharakis N, Krishna S, Yu Z, Gasmi B, et al.
Cancer Immunol Res
. 2022 Jun;
10(8):932-946.
PMID: 35749374
Adoptive cellular therapy (ACT) targeting neoantigens can achieve durable clinical responses in patients with cancer. Most neoantigens arise from patient-specific mutations, requiring highly individualized treatments. To broaden the applicability of...
9.
Nema S, Krishna S, Tiwari A, Bharti P
Trans R Soc Trop Med Hyg
. 2022 Jun;
116(12):1162-1171.
PMID: 35724244
Background: Haem detoxification protein (HDP) is a significant protein in the erythrocytic stage of the Plasmodium lifecycle. HDP could be of paramount interest as a diagnostic biomarker for accurate diagnosis...
10.
Hanada K, Zhao C, Gil-Hoyos R, Gartner J, Chow-Parmer C, Lowery F, et al.
Cancer Cell
. 2022 Apr;
40(5):479-493.e6.
PMID: 35452604
A common theme across multiple successful immunotherapies for cancer is the recognition of tumor-specific mutations (neoantigens) by T cells. The rapid discovery of such antigen responses could lead to improved...